| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;41:842.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
From the Division of Hypertension, University of Michigan (A.B.W., M.C.D., L.G.), Ann Arbor; the Department of Preventive Medicine and Epidemiology, Loyola University Medical Center (X.Z., D.K.), New Orleans, La; and McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine (A.C.), Baltimore, Md.
Correspondence to Alan B. Weder, MD, Division of Hypertension, 3918 Taubman Center, Box 0356, University of Michigan, Ann Arbor, MI 48109. E-mail aweder{at}umich.edu
Increased activity of erythrocyte sodium-lithium countertransport is associated with essential hypertension. Sodium-lithium countertransport is highly heritable, but no single gene product mediating the exchange or explaining the association of increased sodium-lithium countertransport activity and hypertension has been identified. We performed a linkage study by using erythrocyte sodium-lithium countertransport as a quantitative phenotype and genome-wide markers at an average resolution of
10 cM to identify quantitative trait loci explaining sodium-lithium countertransport activity. A peak LOD score of 2.83 was detected on chromosome 15q at D15S642, a marker previously shown to be linked to blood pressure. Several genes mapped to this region are possible candidates for factors affecting erythrocyte sodium-lithium countertransport and/or blood pressure. Further studies confirming the presence of a quantitative trait locus in this region and evaluating these candidate genes may help explain the association of elevated sodium-lithium countertransport and hypertension.
Key Words: hypertension, essential erythrocytes membranes genes genetics
This article has been cited by other articles:
![]() |
C. G. Savopoulos, A. I. Hatzitolios, N. A. Katsiki, M. Baltatzi, M. Kosmidou, N. Raikos, D. P. Mikhailidis, A. G. Ziakas, G. Kaiafa, and N. Tsesmeli Sodium-Lithium Countertransport Activity in Healthy, Dyslipidemic, and Hypertensive Individuals Angiology, January 1, 2009; 59(6): 727 - 735. [Abstract] [PDF] |
||||
![]() |
B. Joe, N. E. Letwin, M. R. Garrett, S. Dhindaw, B. Frank, R. Sultana, K. Verratti, J. P. Rapp, and N. H. Lee Transcriptional profiling with a blood pressure QTL interval-specific oligonucleotide array Physiol Genomics, November 17, 2005; 23(3): 318 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Farjah, T. L. Washington, B. P. Roxas, D. L. Geenen, and R. S. Danziger Dietary NaCl Regulates Renal Aminopeptidase N: Relevance to Hypertension in the Dahl Rat Hypertension, February 1, 2004; 43(2): 282 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zerbini, D. Gabellini, D. Ruggieri, and A. Maestroni Increased Sodium-Lithium Countertransport Activity: A Cellular Dysfunction Common to Essential Hypertension and Diabetic Nephropathy J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S81 - 84. [Abstract] [Full Text] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |